GlassScriptPhysician profile
Kimalyn A Dumas
NPI 1174505101
$3,283.16
in general payments reported to CMS, 2019-2025
26 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.95 · 2022: $122 · 2023: $246 · 2024: $1,391 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,111.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $483.80 | 2022-2025 | |
| Lilly USA, LLC | $379.44 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Sumitomo Pharma America, INC. | $349.40 | 2024-2025 | Gemtesa |
| Pfizer INC. | $311.83 | 2022-2025 | |
| Glaxosmithkline, LLC. | $311.14 | 2022-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $248.79 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $243.46 | 2024-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $189.22 | 2024-2025 | |
| Novo Nordisk INC | $153.58 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $111.66 | 2023-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $73.65 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.98 | 2025 | |
| Shionogi INC | $50.22 | 2021-2023 | Fetroja |
| Acadia Pharmaceuticals INC | $49.31 | 2025 | Daybue |
| Daiichi Sankyo INC. | $42.27 | 2023-2024 | Injectafer |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $39.23 | 2025 | |
| Phathom Pharmaceuticals, INC. | $31.73 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $26.31 | 2024 | Watchman Access System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.67 | 2025 | Caplyta |
| Shield Therapeutics INC | $21.49 | 2024 | |
| Abbott Laboratories | $17.36 | 2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $16.74 | 2023 | Verquvo, Januvia, Belsomra |
| Avanir Pharmaceuticals, INC. | $14.21 | 2021 | |
| Lundbeck LLC | $14.19 | 2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.19 | 2025 | Xifaxan |
| Astellas Pharma US INC | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimalyn Dumas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.